Skip to main content

Table 4 Comparison with related studies

From: Metaplastic breast cancer: a comparison between the most common histologies with poor immunohistochemistry factors

Author Histology Age (years) CS % TN % QX % CT % RT % 5-year OS 5-year DFS
Jung et al. (2010) MCB n = 35 47.4 I 17.1 II 60.0 III 8.6 IV 8.6 X 1.0 80.0 MRM 48.6 BCS 51.4 No 0.0 88.6 71.4 62.8 41.8
  IDC n = 2,839 48.3 I 41.7 II 42.6 III 13.7 IV 2.0 X 0.0 16.7 MRM 24.3 BCS 74.8 No 1.0 80.6 82.1 92 87.3
  TN-IDC n = 473 48.1 I 40.4 II 46.5 III 11.2 IV 2.1 X 0.0 NA MRM 31.7 BCS 67.7 No 0.6 90.5 84.1 83.6 81.8
Bae et al. (2011) [33] MCB n = 47 47.0 I 23.4 II 70.2 III 6.4 93.6 MRM 21.3 BCS 78.7 89.4 80.9 NA 3 years 78.1
  IDC n = 1,346 48.6 I 37.8 II 47.2 III 15.0 16.2 MRM 41.0 BCS 59.0 81 67.4 NA 3 years 91.9
  TN-IDC n = 218 47.9 I 32.6 II 54.6 III 12.8 NA MRM 33.9 BCS 66.1 90.9 73.9 NA 3 years 84.9
Song et al. (2013) [32] MCB n = 55 ≤50 = 49.1% >50 = 50.1% I 7.3 II 54.6 III 29.1 X 9.1 67.3 MRM 92.7 BCS 7.7 48 49.1 54.5 45.5
  IDC n = 767 ≤50 = 52.8% >50 = 47.2% I 14.0 II 54.6 III 29.1 X 6.7 18.4 MRM 82.5 BCS 17.5 81.7 23.1 85.1 71.2
  TN-IDC n = 131 ≤50 = 58.0% >50 = 42.0% I 16.0 II 70.2 III 6.11 X 7.6 NA MRM 80.9 BCS 19.1 80.9 27.1 73.3 60.3
Nelson et al. (2014) [38] MCB n = 1,011 61 I 26.4 II 64.2 III 9.4 ER/PR (-) 77.8% MRM 53.0 BCS 47.0 NA 48.3 71 *71 NA
  IDC n = 253,818 59 I 56.1 II 35.7 III 8.2 ER/PR (-) 21.3% MRM 38.3 BCS 61.7 NA 54.3 88 *81 NA
Wright et al. (2014) [39] MCB n = 2,338 NA I 25.6 II 55.7 III 12.6 IV 6.0 ER/PR (-) 79.0% NA NA NA 62.2 *63.5 NA
  IDC n = 382,667 NA I 52.2 II 30.7 III 12.7 IV 4.3 ER/PR (-) 22.2% NA NA NA 81.2 *72.2 NA
  ILC n = 44,813 NA I 41.9 II 33.1 III 18.8 IV 6.3 ER/PR (-) 3.8% NA NA NA 80.2 *59.5 NA
Barquet et al. (Current study) MCB n = 24 49.6 II 37.5 III 54.2 IV 8.3 83.6 MRM 91.7 BCS 0.0 No 8.3 ind CT 50.0 adj CT 45.8 58.3 72.2 52.1
  HG-IDC n = 37 49.3 II 37.5 III 54.2 IV 8.3 40.0 MRM 79.2 BCS 6.3 No 14.6 ind CT 79.2 adj CT 39.6 47.9 73.7 55.4
  TN-IDC n = 48 49.5 II 37.5 III 54.2 IV 8.3 NA MRM 77.1 BCS 14.6 No 8.3 ind CT 81.3 adj CT 75 56.3 84.8 60.1
  TN-ILC n = 48 53.5 II 13.5 III 70.2 IV 16.2 NA MRM 64.9 BCS 0.0 No 35.1 ind CT 54.1 adj CT 59.5 59.5 44.3 29.9
  1. CS: clinical stage; TN: triple negative; QX: type of surgery; CT: chemotherapy; RT: radiotherapy; OS: overall survival; DFS: disease-free survival; MCB: metaplastic carcinoma of the breast; IDC: invasive ductal carcinoma; TN-IDC: triple-negative invasive ductal carcinoma; ILC: invasive lobular carcinoma; ER/PR(-): negative estrogen and progesterone receptors; HG-IDC: high-grade invasive ductal carcinoma; TN-IDC: triple-negative invasive ductal carcinoma; TN-ILC: triple-negative invasive lobular carcinoma; X: not known; NA: not applicable; MRM: modified radical mastectomy; BCS: breast conservative surgery; ind CT: induction chemotherapy: adj CT: adjuvant chemotherapy; *OS in ER(-)/PR(-).